$Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy$

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy

BackgroundBruton tyrosine kinase inhibitors (BTKis) interrupt B-cell receptor signaling and thereby could potentially reactivate hepatitis B virus (HBV). However, data about the risk for HBV reactivation (HBVr) of BTKis in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) patients are...

Full description

Bibliographic Details
Main Authors:	Ying Ni, Lixia Gao, Yan Lu, Shiguang Ye, Lili Zhou, Wenbin Qian, Aibin Liang, Ping Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Immunology
Subjects:	HBV reactivation diffuse large B-cell lymphoma Bruton tyrosine kinase inhibitor resolved HBV infection prognosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.982346/full

Similar Items

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
by: Ping Li, et al.
Published: (2021-07-01)

Editorial: HBV and lymphoma
by: Giuseppe Gentile, et al.
Published: (2023-07-01)

Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study
by: Wenxue Guan, et al.
Published: (2022-11-01)

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
by: Liang Wang, et al.
Published: (2021-04-01)

A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma
by: Yong Xia, et al.
Published: (2023-12-01)

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
by: Dariusz Rozkiewicz, et al.
Published: (2023-03-01)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
by: Debora Basile, et al.
Published: (2019-06-01)

Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
by: Jing Shen, et al.
Published: (2022-11-01)

Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective
by: Yekta Ghane, et al.
Published: (2023-12-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
by: Yaya Chu, et al.
Published: (2019-01-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Abdullah Mohammad Khan
Published: (2022-04-01)

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases
by: Yu. S. Torshina, et al.
Published: (2023-06-01)

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
by: Simei Qiu, et al.
Published: (2021-08-01)

HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review
by: Giuseppe Gentile, et al.
Published: (2019-11-01)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
by: Max Von Suskil, et al.
Published: (2021-05-01)

Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study
by: Yu-Fen Tsai, et al.
Published: (2019-09-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
by: Gaurav Nepal, et al.
Published: (2022-01-01)

Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia
by: V.D. Ramalho, et al.
Published: (2010-09-01)

Evaluation of the Prevalence of Hepatitis B and C in Patients with Lymphoma
by: Mahmut BÜYÜKŞİMŞEK, et al.
Published: (2020-04-01)

"Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia "
by: "Asghar Aghamohammadi, et al.
Published: (2004-12-01)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
by: Piyu Parth Naik
Published: (2022-01-01)

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
by: Aikaterini Patsatsi, et al.
Published: (2021-08-01)

HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors
by: Jiaming Shen, et al.
Published: (2023-05-01)

Inhibition of Bruton's Tyrosine Kinase Protects Against Burn Sepsis-Induced Intestinal Injury
by: Jia Wan, et al.
Published: (2022-02-01)

Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase
by: Eun Lee, et al.
Published: (2020-10-01)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
by: Skye Montoya, et al.
Published: (2023-07-01)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
by: Carlotta Cerva, et al.
Published: (2022-02-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
by: Antonio García-Merino
Published: (2021-09-01)

Bruton’s Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis
by: Rachel H. Bonami, et al.
Published: (2022-03-01)

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis
by: Thi Thuy Nguyen, et al.
Published: (2023-03-01)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
by: Stefan F. H. Neys, et al.
Published: (2021-06-01)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
by: Mitra Rezaei, MD, et al.
Published: (2022-01-01)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
by: Zemene Demelash Kifle
Published: (2021-09-01)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
by: Zhou-Peng Xiao, et al.
Published: (2023-03-01)

Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton’s Tyrosine Kinase
by: Yong Du, et al.
Published: (2022-07-01)

Bruton’s Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae
by: Zhe Liu, et al.
Published: (2022-05-01)

Covalent cysteine targeting of Bruton’s tyrosine kinase (BTK) family by withaferin-A reduces survival of glucocorticoid-resistant multiple myeloma MM1 cells
by: Logie, Emilie, et al.
Published: (2021)